Research graph
References from CAR T cell-induced interferon gamma enhances MHC class I expression and sensitizes neuroblastoma to TCR-engineered T cell therapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Landscape of cancer cell therapies: trends and real-world data
10.1038/d41573-022-00095-1 · 2022 · External reference
Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma
10.1002/(sici)1097-0215(19961021)69:5<403::aid-ijc9>3.0.co;2-9 · 1996 · External reference
Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR
10.1002/ijc.22118 · 2007 · External reference
MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors
10.1007/s00432-008-0484-1 · 2009 · External reference
Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen
2003 · External reference
The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas
10.1002/ijc.2910540329 · 1993 · External reference
Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma
1999 · External reference
The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome
10.1158/1078-0432.ccr-03-0813 · 2004 · External reference
Neuroblastoma: molecular pathogenesis and therapy
10.1146/annurev-med-011514-023121 · 2015 · External reference
Characterization of the expression of MHC proteins in human embryonic stem cells
10.1073/pnas.142298299 · 2002 · External reference
Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma
10.1007/s00262-004-0603-z · 2005 · External reference
Neuroblastoma is composed of two super-enhancer-associated differentiation states
10.1038/ng.3899 · 2017 · External reference
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1
10.1038/s43018-022-00405-x · 2022 · External reference
Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell Fas-FasL-dependent AICD
10.1158/2326-6066.cir-14-0200 · 2015 · External reference
Preclinical assessment of CD171-directed CAR T-cell adoptive therapy for childhood neuroblastoma: CE7 epitope target safety and product manufacturing feasibility
10.1158/1078-0432.ccr-16-0354 · 2017 · External reference
Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice
10.1038/nbt.3147 · 2015 · External reference
Generation of effective and specific human TCRs against tumor/testis antigen NY-ESO-1 in mice with humanized T cell recognition system
10.3389/fimmu.2024.1524629 · 2024 · External reference
Production and characterization of monoclonal antibodies against human neuroblastoma
10.3109/07357908309041361 · 1986 · External reference
Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells
10.1016/j.omtm.2022.03.018 · 2022 · External reference
Integration of ζ-deficient CARs into the CD3ζ gene conveys potent cytotoxicity in T and NK cells
10.1182/blood.2023020973 · 2024 · External reference
Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: Optimizing αβ T cell-depleted haploidentical hematopoietic stem cell transplantation
10.3324/haematol.2019.233882 · 2021 · External reference
CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products
10.1182/bloodadvances.2022009397 · 2023 · External reference
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell Malignancies
10.1016/j.ymthe.2022.09.003 · 2023 · External reference
Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression
10.1084/jem.20192203 · 2021 · External reference
Going back to class I: MHC and immunotherapies for childhood cancer
10.1002/pbc.25359 · 2015 · External reference
Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma
10.18632/oncotarget.5657 · 2015 · External reference
Personalized CRISPR knock-in cytokine gene therapy to remodel the tumor microenvironment and enhance CAR T cell therapy in solid tumors
10.1038/s41467-025-67328-w · 2025 · External reference
Enhancement of NF-kappaB expression and activity upon differentiation of human embryonic stem cell line SNUhES3
10.1089/scd.2007.0014 · 2007 · External reference
IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma
10.1371/journal.pone.0046928 · 2012 · External reference
Nedd4-binding protein 1 and TNFAIP3-interacting protein 1 control MHC-1 display in neuroblastoma
10.1158/0008-5472.can-18-0545 · 2018 · External reference
Genetic mechanisms of immune evasion in colorectal cancer
10.1158/2159-8290.cd-17-1327 · 2018 · External reference
Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development
10.1038/s41577-025-01208-8 · 2026 · External reference
MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing
10.1007/s00262-011-1037-z · 2011 · External reference
Complete remission following decitabine/dendritic cell vaccine for relapsed neuroblastoma
10.1542/peds.2012-0376 · 2013 · External reference
Expression evaluated by digital image analysis techniques of PRAME more than MCM6 is associated with poor prognosis in neuroblastoma: A pilot study with 84 cases
10.1016/j.humpath.2025.105718 · 2025 · External reference
Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy
10.1016/j.phrs.2025.107608 · 2025 · External reference
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells
10.1016/j.ccell.2023.11.004 · 2023 · External reference
Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma
10.1002/(sici)1097-0215(19961021)69:5<403::aid-ijc9>3.0.co;2-9 · ExternalCitation · doi-reference
Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR
10.1002/ijc.22118 · ExternalCitation · doi-reference
The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas
10.1002/ijc.2910540329 · ExternalCitation · doi-reference
Going back to class I: MHC and immunotherapies for childhood cancer
10.1002/pbc.25359 · ExternalCitation · doi-reference
Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma
10.1007/s00262-004-0603-z · ExternalCitation · doi-reference
MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing
10.1007/s00262-011-1037-z · ExternalCitation · doi-reference
MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors
10.1007/s00432-008-0484-1 · ExternalCitation · doi-reference
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells
10.1016/j.ccell.2023.11.004 · ExternalCitation · doi-reference
Expression evaluated by digital image analysis techniques of PRAME more than MCM6 is associated with poor prognosis in neuroblastoma: A pilot study with 84 cases
10.1016/j.humpath.2025.105718 · ExternalCitation · doi-reference
Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells
10.1016/j.omtm.2022.03.018 · ExternalCitation · doi-reference
Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy
10.1016/j.phrs.2025.107608 · ExternalCitation · doi-reference
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell Malignancies
10.1016/j.ymthe.2022.09.003 · ExternalCitation · doi-reference
Landscape of cancer cell therapies: trends and real-world data
10.1038/d41573-022-00095-1 · ExternalCitation · doi-reference
Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice
10.1038/nbt.3147 · ExternalCitation · doi-reference
Neuroblastoma is composed of two super-enhancer-associated differentiation states
10.1038/ng.3899 · ExternalCitation · doi-reference
Personalized CRISPR knock-in cytokine gene therapy to remodel the tumor microenvironment and enhance CAR T cell therapy in solid tumors
10.1038/s41467-025-67328-w · ExternalCitation · doi-reference
Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development
10.1038/s41577-025-01208-8 · ExternalCitation · doi-reference
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1
10.1038/s43018-022-00405-x · ExternalCitation · doi-reference
Characterization of the expression of MHC proteins in human embryonic stem cells
10.1073/pnas.142298299 · ExternalCitation · doi-reference
Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression
10.1084/jem.20192203 · ExternalCitation · doi-reference
Enhancement of NF-kappaB expression and activity upon differentiation of human embryonic stem cell line SNUhES3
10.1089/scd.2007.0014 · ExternalCitation · doi-reference
Neuroblastoma: molecular pathogenesis and therapy
10.1146/annurev-med-011514-023121 · ExternalCitation · doi-reference
Nedd4-binding protein 1 and TNFAIP3-interacting protein 1 control MHC-1 display in neuroblastoma
10.1158/0008-5472.can-18-0545 · ExternalCitation · doi-reference
The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome
10.1158/1078-0432.ccr-03-0813 · ExternalCitation · doi-reference
Preclinical assessment of CD171-directed CAR T-cell adoptive therapy for childhood neuroblastoma: CE7 epitope target safety and product manufacturing feasibility
10.1158/1078-0432.ccr-16-0354 · ExternalCitation · doi-reference
Genetic mechanisms of immune evasion in colorectal cancer
10.1158/2159-8290.cd-17-1327 · ExternalCitation · doi-reference
Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell Fas-FasL-dependent AICD
10.1158/2326-6066.cir-14-0200 · ExternalCitation · doi-reference
Integration of ζ-deficient CARs into the CD3ζ gene conveys potent cytotoxicity in T and NK cells
10.1182/blood.2023020973 · ExternalCitation · doi-reference
CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products
10.1182/bloodadvances.2022009397 · ExternalCitation · doi-reference
IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma
10.1371/journal.pone.0046928 · ExternalCitation · doi-reference
Complete remission following decitabine/dendritic cell vaccine for relapsed neuroblastoma
10.1542/peds.2012-0376 · ExternalCitation · doi-reference
Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma
10.18632/oncotarget.5657 · ExternalCitation · doi-reference
Production and characterization of monoclonal antibodies against human neuroblastoma
10.3109/07357908309041361 · ExternalCitation · doi-reference
Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: Optimizing αβ T cell-depleted haploidentical hematopoietic stem cell transplantation
10.3324/haematol.2019.233882 · ExternalCitation · doi-reference
Generation of effective and specific human TCRs against tumor/testis antigen NY-ESO-1 in mice with humanized T cell recognition system
10.3389/fimmu.2024.1524629 · ExternalCitation · doi-reference
